BIT Capital GmbH Has $1.21 Million Stock Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Key Points

• BIT Capital GmbH reduced its stake in Immunocore Holdings by 39.9% in the first quarter, now owning 40,787 shares valued at approximately $1.21 million.
• Immunocore has seen a 33.6% increase in revenue year-over-year, reporting $125.13 million for the latest quarter, significantly exceeding analysts' expectations.
• Analysts maintain a positive outlook for Immunocore, with multiple firms issuing "buy" ratings and price targets ranging from $65.00 to $100.00.

BIT Capital GmbH reduced its stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 39.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,787 shares of the company's stock after selling 27,053 shares during the period. BIT Capital GmbH owned about 0.08% of Immunocore worth $1,210,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Immunocore in the 4th quarter valued at about $25,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Immunocore during the 1st quarter worth about $225,000. Tema Etfs LLC bought a new stake in shares of Immunocore during the 4th quarter worth about $330,000. Virtus ETF Advisers LLC raised its position in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after buying an additional 3,238 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Immunocore by 22.2% in the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock worth $557,000 after purchasing an additional 3,437 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Immunocore from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunocore in a research report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 target price on the stock. JPMorgan Chase & Co. dropped their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Immunocore currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Stock Performance

Immunocore stock traded up $0.10 on Thursday, hitting $32.20. The company's stock had a trading volume of 179,790 shares, compared to its average volume of 336,066. The firm has a market cap of $1.62 billion, a P/E ratio of -74.93 and a beta of 0.77. The company has a quick ratio of 6.31, a current ratio of 6.36 and a debt-to-equity ratio of 1.03. The company has a fifty day moving average price of $34.30 and a 200-day moving average price of $31.21. Immunocore Holdings PLC Sponsored ADR has a one year low of $23.15 and a one year high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. During the same period last year, the business posted ($0.23) EPS. The company's revenue was up 30.0% compared to the same quarter last year. On average, equities analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.